首頁 > 市場調查報告書 > 製藥

生物標記循環系統

市場調查報告書

商品編碼

1593527

心臟生物標記市場規模、佔有率和成長分析（按產品、應用、測試地點和地區）：產業預測（2024-2031）

Cardiac Biomarkers Market Size, Share, Growth Analysis, By Product (Troponin, CK-MB), By Application (Acute Coronary Syndrome, Myocardial Infarction), By Location of Testing, By Region - Industry Forecast 2024-2031

出版日期: 2024年11月11日 | 出版商:

SkyQuest | 英文 199 Pages | 商品交期: 3-5個工作天內

價格

簡介目錄

2022年全球心臟生物標記市場規模為94.2億美元，從2023年的106.1億美元成長到2031年的275.6億美元，在預測期內（2024-2031年）預計複合年成長率為12.67%。年）。

在心臟病盛行率不斷上升、人們對早期診斷益處的認知不斷提高以及對個人化醫療的需求不斷成長的推動下，心臟生物標記市場有望顯著成長。在心臟受到壓力或受傷時釋放到血液中的生物標記在各種心臟疾病（包括心臟衰竭和心臟病發作）的診斷和治療中發揮重要作用。生物標記檢測的技術進步進一步刺激市場擴張。然而，挑戰仍然存在，特別是先進生物標記測試的高成本和缺乏標準化，這可能導致測試結果的變異性。儘管存在這些障礙，整體市場前景仍然樂觀。這是由持續的技術創新、對預防性醫療保健的濃厚興趣以及不斷上漲的醫療保健成本所推動的。隨著情況的發展，心臟生物標記行業預計將穩定並成長，以滿足對抗循環系統疾病的有效診斷解決方案不斷成長的需求。

市場概況
北美洲
- 美國
- 加拿大
歐洲
- 德國
- 西班牙
- 法國
- 英國
- 義大利
- 其他歐洲國家
亞太地區
- 中國
- 印度
- 日本
- 韓國
- 其他亞太地區
拉丁美洲
- 巴西
- 其他拉丁美洲
中東和非洲 (MEA)
- 波灣合作理事會(GCC) 國家
- 南非
- 其他中東/非洲

競爭格局

前5名企業對比
主要企業市場定位（2023年）
主要市場參與者所採取的策略
近期市集活動
主要企業市場佔有率（2023年）

主要企業簡介

Abbott
QuidelOrtho Corporation
Siemens AG
F. Hoffmann-La Roche Ltd.
Danaher Corporation
Biomerieux SA
Bio-Rad Laboratories, Inc.
Randox Laboratories Ltd.
Creative Diagnostics
Life Diagnostics
Thermo Fisher Scientific
Becton, Dickinson and Company
DiaSorin
Myriad RBM
Mindray Medical International Limited
ReLIA Diagnostic Systems
Merck KGaA
Quanterix Corporation
Eurofins Scientific
Inova Diagnostics

簡介目錄

Product Code: SQMIG35A2951

Global Cardiac Biomarkers Market size was valued at USD 9.42 billion in 2022 and is poised to grow from USD 10.61 billion in 2023 to USD 27.56 billion by 2031, growing at a CAGR of 12.67% during the forecast period (2024-2031).

The cardiac biomarkers market is poised for considerable growth, propelled by a rising prevalence of heart diseases, heightened awareness about the advantages of early diagnosis, and an increasing demand for personalized medicine. These biomarkers, released into the bloodstream during heart stress or damage, play a crucial role in diagnosing and managing various cardiac disorders, including heart failure and heart attacks. Technological advancements in biomarker detection are further stimulating market expansion. However, challenges persist, notably the high costs of advanced biomarker tests and a lack of standardization, which can result in inconsistencies in test outcomes. Despite these hurdles, the overall market outlook remains optimistic, driven by ongoing innovations, a strong focus on preventive healthcare, and escalating healthcare expenditures. As the landscape evolves, the cardiac biomarkers sector is expected to stabilize and thrive, catering to an increasing demand for effective diagnostic solutions in the fight against cardiovascular diseases.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Cardiac Biomarkers market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Cardiac Biomarkers Market Segmental Analysis

Global Cardiac Biomarkers Market is segmented by Product, Application, Location of Testing, and Region. Based on Product, the market is segmented into Troponin, CK-MB, Myoglobin, BNP and NT-proBNP, Others. Based on Application, the market is segmented into Acute Coronary Syndrome, Myocardial Infarction, Congestive Heart Failure, Others. Based on Location of Testing, the market is segmented into Laboratory Testing, Point of Care Testing. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Cardiac Biomarkers Market

The increasing emphasis on preventive healthcare and early diagnosis is a significant market driver for the global cardiac biomarkers market. As healthcare systems worldwide shift from reactive to proactive approaches, there is a growing demand for innovative diagnostic tools that can identify cardiovascular diseases at an early stage. This trend is fueled by rising awareness about heart disease prevalence and the economic burden associated with late-stage interventions. Moreover, advancements in biomarker technology and the integration of personalized medicine enable healthcare providers to offer tailored treatment plans, further promoting demand for cardiac biomarkers, thereby driving market growth.

Restraints in the Global Cardiac Biomarkers Market

One of the significant market restraints for the global cardiac biomarkers market is the ongoing challenges related to biomarker reliability and validation. The complexity of the biological processes involved in cardiovascular diseases makes it difficult to ensure that biomarkers are consistently reliable across diverse populations and clinical settings. This lack of standardization can lead to variability in test results, which hinders the widespread adoption of these diagnostic tools. Furthermore, regulatory hurdles and the lengthy validation process for new biomarkers can delay market entry and contribute to costly investments, ultimately restricting innovation and limiting the growth potential of the cardiac biomarkers sector.

Market Trends of the Global Cardiac Biomarkers Market

The Global Cardiac Biomarkers market is experiencing a notable trend towards the adoption of multi-biomarker panels, reflecting a shift from traditional single biomarker assessments. This approach allows for comprehensive evaluation of cardiovascular risk factors, encompassing stress, cardiac injury, and inflammation. As healthcare providers increasingly recognize the limitations of individual biomarkers, multi-biomarker methodologies are being explored to enhance risk stratification, particularly in complex cases where single markers may fall short. This trend is expected to drive innovation and growth in the market, as the demand for more accurate and holistic cardiovascular diagnostics continues to escalate.

Introduction

Objectives of the Study
Definitions
Market Scope

Research Methodology

Information Procurement
Secondary & Primary Data Sources
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Market Overview Outlook
Supply Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges
Porters Analysis
- Competitive rivalry
- Threat of Substitute Products
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers

Key Market Insights

Key Success Factor
Degree of Competition
Top Investment Pockets
Ecosystem of the Market
Technology Analysis
Patent Analysis
Value Chain Analysis
Regulatory Analysis

Cardiac Biomarkers Market By Product

Market Overview
Troponin
CK-MB
Myoglobin
BNP & NT-proBNP
Others

Cardiac Biomarkers Market By Application

Market Overview
Acute Coronary Syndrome
Myocardial Infarction
Congestive Heart Failure
Others

Cardiac Biomarkers Market By Location of Testing

Market Overview
Laboratory Testing
Point of Care Testing

Cardiac Biomarkers Market Size by Region

Market Overview
North America
- USA
- Canada
Europe
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America
- Brazil
- Rest of Latin America
Middle East & Africa (MEA)
- GCC Countries
- South Africa
- Rest of MEA

Competitive Landscape

Top 5 Player Comparison
Market Positioning of Key Players, 2023
Strategies Adopted by Key Market Players
Recent Activities in the Market
Key Companies Market Share (%), 2023

Key Company Profiles

Abbott
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
QuidelOrtho Corporation
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Siemens AG
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
F. Hoffmann-La Roche Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Danaher Corporation
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Biomerieux SA
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bio-Rad Laboratories, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Randox Laboratories Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Creative Diagnostics
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Life Diagnostics
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Thermo Fisher Scientific
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Becton, Dickinson and Company
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
DiaSorin
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Myriad RBM
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Mindray Medical International Limited
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
ReLIA Diagnostic Systems
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Merck KGaA
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Quanterix Corporation
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Eurofins Scientific
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Inova Diagnostics
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments